Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results

Figure 1 Outline of the study cohort. Five hundred and eight patients initiated treatment. The number of patients with confirmed outcomes [sustained virological response (SVR) 12 or non-SVR12], the number with imputed outcomes, and the number who were lost to follow-up on each of three regimens are indicated. SVR: Sustained virological response; SMV: Simeprevir; SOF: Sofosbuvir; RBV: Ribavirin; PEG: Pegylated interferon.

Figure 2 Forest plot of sustained virological response 12 rates for 470 patients with confirmed outcomes. A: SMV/SOF ± RBV; B: SOF/RBV; C: SOF/PEG/RBV. Dotted lines represent the separation of categories. The sustained virological response 12 rate, number in each subgroup, and P value of the categorical comparison are shown below the graph. SMV: Simeprevir; SOF: Sofosbuvir; RBV: Ribavirin; PEG: pegylated-interferon.